Gallery
- PM Modi visit USAOnly the mirror in my washroom and phone gallery see the crazy me : Sara KhanKarnataka rain fury: Photos of flooded streets, uprooted treesCannes 2022: Deepika Padukone stuns at the French Riviera in Sabyasachi outfitRanbir Kapoor And Alia Bhatt's Wedding Pics - Sealed With A KissOscars 2022: Every Academy Award WinnerShane Warne (1969-2022): Australian cricket legend's life in picturesPhotos: What Russia's invasion of Ukraine looks like on the groundLata Mangeshkar (1929-2022): A pictorial tribute to the 'Nightingale of India'PM Modi unveils 216-feet tall Statue of Equality in Hyderabad (PHOTOS)
Indian men's hockey team captain Harmanpreet Singh has been named Player of the Year 2024
- World Boxing medallist Gaurav Bidhuri to flag off 'Delhi Against Drugs' movement on Nov 17
- U23 World Wrestling Championship: Chirag Chikkara wins gold as India end campaign with nine medals
- FIFA president Infantino confirms at least 9 African teams for the 2026 World Cup
- Hockey, cricket, wrestling, badminton, squash axed from 2026 CWG in Glasgow
- FIFA : Over 100 female footballers urge FIFA to reconsider partnership with Saudi oil giant
Inactivated vaccines are safest with lesser adverse reactions: Bharat Biotech Last Updated : 21 Dec 2020 03:01:05 AM IST Bharat Biotech workers Bharat Biotech has claimed that amongst all the vaccine platforms such as an mRNA-based vaccine, DNA-based vaccine, vector-based vaccine, or live attenuated vaccines, etc., the inactivated vaccines being developed by it for Covid 19 are safest, and hence, the adverse reactions are lesser.
In a series of frequently asked questions (FAQs) for its trials, Bharat Biotech said BBV-152 is a whole-virion inactivated SARS-CoV-2 vaccine. Amongst all the vaccine platforms such as an mRNA-based vaccine, DNA-based vaccine, vector-based vaccine, or live attenuated vaccines, etc., the inactivated vaccines are safest, and hence, the adverse reactions are lesser.It said about 755 participants have been vaccinated in phase 1 & 2 clinical trials. No serious adverse events have been reported to be related to the vaccine in phase 1 and 2 clinical trials.It said vaccination with BBV-152B may protect the participants only after 14-days post-second dose of vaccination. Hence, the participants should follow the below precautions to avoid SARSCoV-2 infection up to 14-days post-second dose of vaccination.Since the participants are vaccinated before the results of the RT-PCR and the ELISA tests are known, there is a chance that the participants with asymptomatic SARS-CoV-2 infection may enter the study, and later show Covid-19 symptoms.Also, the participants who are very recently infected with SARS-CoV-2just before the first dose of vaccination, and have viral loads below the limit of detection (LoD) of the RTPCR test kit, may not be detected by RT-PCR, and later show the Covid-19 symptoms.Since there is also an equal chance of getting a placebo for every participant, 50 per cent of the participant will get the placebo, and they may get SARS-CoV-2 infection/Covid-19 any time after vaccination.Bharat Biotech said in the event of successful evidence of efficacy detected during the interim analysis, participants who received placebo may be provided with vaccination at the end of the study, after getting due approval from the regulatory authorities.It said that whenever a vaccine get approval first Health care workers, Front line workers will receive vaccine. It will take at least 6 months for elderly (more than 65 years to receive the vaccine).It will take a minimum of 6-12 months for a person under the ages of 60 to receive a vaccine, due to limited supply."If you participate in this trial, this vaccine will most likely get licensed within a few months. And if you received a placebo, we will contact you and give you the vaccine, thus giving you priority access to the vaccine (even if you are below 60 years)," it said.IANS New Delhi For Latest Updates Please-
Join us on
Follow us on
172.31.16.186